China
Africa
Explore chapters and articles related to this topic
Pyridoxine
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
A 52-year-old man used 2 steroid creams, one with hydrocortisone 17-butyrate, the other with dexamethasone and pyridoxine HCI for the treatment of a mild burn. Erythema and vesicles developed around the initial lesion 3 days later followed by edema and erosions. By the 7th day the patient started to develop similar lesions on other parts of the body. Patch tests showed positive reactions to the cream with hydrocortisone 17-butyrate at D4 and the other cream at D10. A second test with the components of the creams showed positive reactions at D4 to hydrocortisone 17-butyrate 0.1% and pyridoxine HCI 1%. Finally, several steroids and vitamin B6 derivatives were tested. At D4, there were positive reactions to 1% pyridoxine HCI, 1% pyridoxal HCI and 1% pyridoxal 5-phosphate, but pyridoxamine was negative. It was suggested that the allergy to pyridoxine was caused by active sensitization, as the patch test had become positive at D10 only (3). This is certainly possible, but nowadays it is known that reactions at D10 need not necessarily indicate patch test sensitization.
Systemic Contact Dermatitis
Published in Kirsti Kauppinen, Kristiina Alanko, Matti Hannuksela, Howard Maibach, Skin Reactions to Drugs, 2020
SCD reactions to corticosteroids have gained much attention in recent years. Most reports deal with single cases, and only in sporadic cases challenge tests have been routinely performed (see Reference 52). In a 69-year-old female patient who had experienced five episodes of systemic reactions from intravenous corticosteroids given for her asthma, intradermal tests with hydrocortisone phosphate, 1 and 10 mg/ml, and with methylprednisolone, 0.4 and 4.0 mg/ml, produced in 6 hours a local and then a systemic pruritic erythematous reaction.44 A 55-year-old female patient with SCD from methylprednisolone tolerated well paramethasone and fluocortolone in therapeutic doses.41 Reappearance of positive PTs after a peroral challenge with 100 mg of hydrocortisone was noticed in two patients with positive PTs to hydrocortisone and hydrocortisone-17-butyrate.9 In the same study, 250 mg of hydrocortisone produced erythematous and edematous rash in two other patients with both hydrocortisone and hydrocortisone-17-butyrate allergy. Two patients with negative PT to hydrocortisone and positive PT to hydrocortisone-17-butyrate did not react to 250 mg of peroral hydrocortisone.9
Topical Corticosteroids
Published in Vineet Relhan, Vijay Kumar Garg, Sneha Ghunawat, Khushbu Mahajan, Comprehensive Textbook on Vitiligo, 2020
Deepika Pandhi, Vandana Kataria
In 2008, Sassi et al. compared topical hydrocortisone 17-butyrate in combination with laser versus laser used as a monotherapy. A statistically significant difference in favor of the combination treatment was observed. Participants on combination therapy were more than twice as likely to achieve 75% repigmentation than those receiving laser treatment alone [17]. Combination treatment of hydrocortisone 17-butyrate with 308 excimer laser has also been documented to be synergistic in the same study.
Allergy against Steroids in Ocular Inflammation
Published in Ocular Immunology and Inflammation, 2021
Luz Elena Concha-Del Rio, Pilar Uribe-Reina, Alejandra De-La-Torre
The most common route of sensitization of this type of reactions is the cutaneous application. Other routes have been described, such as aerosols.25 In order to understand the physiopathology of delayed reactions, it is important to know the chemical CS structure. CS basic ring is cyclopentanoperhydrophenanthrene, which suffers modifications such as esterification and halogenation in pursuance of improving therapeutics properties. This common characteristic is known to lead to cross-reactions.19 Coopman classification categorizes CS into four groups in the function of their allergenicity: A (hydrocortisone type, methylprednisolone, prednisolone, prednisone), B (triamcinolone acetonide type, budesonide, fluocinolone), C (betamethasone type, dexamethasone), and D (hydrocortisone-17-butyrate type, clobetasol).26 Later, Group D was later subdivided into two groups, D1 and D2, depending on the presence of a C16 methyl substitution and/or halogenation on the C9 of the B ring.17 It is demonstrated that members of a group cross-react with each other, but no with CS belonging to a different group.19
Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis
Published in Expert Opinion on Drug Safety, 2020
Victoria Amat-Samaranch, Lluís Puig
Another phase I trial re-assessed the corticosteroid potency of BD in Cal/BD foam after exposure for a longer time (16 h instead of 6 h). It revealed that Cal/BD foam has a potency not significantly different from BD 0.05% ointment and mometasone furoate 0.1% cream, it is less potent than clobetasol propionate 0.05% cream and it is more potent than hydrocortisone-17-butyrate 0.1% ointment [45].
Vasoconstrictor potency of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam versus other topical corticosteroids used to treat psoriasis vulgaris
Published in Journal of Dermatological Treatment, 2019
C. Queille-Roussel, J. Nielsen, J.-P. Lacour
The treatments used in this study were Cal/BD cutaneous foam, CP 0.05% cream (very potent), BD 0.05% ointment (potent), mometasone furoate 0.1% cream (MF; potent), hydrocortisone-17-butyrate 0.1% ointment (HB; moderately potent) and cutaneous foam vehicle.